https://www.sciencedirect.com/science/article/pii/S258893112400176
An interesting article, which concludes:
The worldwide GAP3 registry is unique in size and duration of follow-up. In appropriate patients initiating AS, the prognosis is excellent and the approach is safe. Long-term trends indicate that, over time, intervention rates have decreased, and eligibility has expanded, likely reflecting increased confidence in the safety of the approach, and incorporation of imaging into the AS algorithm. The clinical outcomes from the GAP3 database robustly support the view that AS should be the gold standard for low-risk PCa management.
Edited by member 13 Aug 2025 at 08:42
| Reason: Add link